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Abstract
Introduction: Quiescin sulfhydryl oxidase 1 (QSOX1) oxidizes sulfhydryl groups to form disulfide bonds in proteins.
Tumor specific expression of QSOX1 has been reported for numerous tumor types. In this study, we investigate
QSOX1 as a marker of breast tumor progression and evaluate the role of QSOX1 as it relates to breast tumor
growth and metastasis.
Methods: Correlation of QSOX1 expression with breast tumor grade, subtype and estrogen receptor (ER) status was
gathered through informatic analysis using the “Gene expression based Outcome for Breast cancer Online” (GOBO)
web-based tool. Expression of QSOX1 protein in breast tumors tissue microarray (TMA) and in a panel of breast
cancer cell lines was used to confirm our informatics analysis. To investigate malignant cell mechanisms for which
QSOX1 might play a key role, we suppressed QSOX1 protein expression using short hairpin (sh) RNA in ER+ Luminal
A-like MCF7, ER+ Luminal B-like BT474 and ER- Basal-like BT549 breast cancer cell lines.
Results: GOBO analysis revealed high levels of QSOX1 RNA expression in ER+ subtypes of breast cancer. In addition,
Kaplan Meyer analyses revealed QSOX1 RNA as a highly significant predictive marker for both relapse and poor overall
survival in Luminal B tumors. We confirmed this finding by evaluation of QSOX1 protein expression in breast tumors and
in a panel of breast cancer cell lines. Expression of QSOX1 in breast tumors correlates with increasing tumor grade and
high Ki-67 expression. Suppression of QSOX1 protein slowed cell proliferation as well as dramatic inhibition of MCF7,
BT474 and BT549 breast tumor cells from invading through Matrigel™ in a modified Boyden chamber assay. Inhibition
of invasion could be rescued by the exogenous addition of recombinant QSOX1. Gelatin zymography indicated that
QSOX1 plays an important role in the function of MMP-9, a key mediator of breast cancer invasive behavior.
Conclusions: Taken together, our results suggest that QSOX1 is a novel biomarker for risk of relapse and poor
survival in Luminal B breast cancer, and has a pro-proliferative and pro-invasive role in malignant progression partly
mediated through a decrease in MMP-9 functional activity.
Introduction
Breast adenocarcinoma is the most common cancer diag-
nosed in women throughout the world [1]. In 2012, an
estimated 226,870 new cases of invasive breast cancer are
expected to occur among US women, and an estimated
39,510 breast cancer deaths [2,3]. Despite significant
advances in subtype classification of breast cancers, con-
text-specific drivers of invasion and metastasis are still
poorly understood. Our laboratory has focused on defin-
ing tumor-specific expression of proteins predicted to
play an important role in malignant tumor biology.
Recently our lab reported the identification of a short
peptide that maps back to the C-terminus of QSOX1 in
plasma from pancreatic cancer patients [4]. Subsequently,
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we found that QSOX1 is over-expressed in tumor tissue
from pancreatic cancer patients, but not adjacent normal
tissue [5]. In vitro studies with pancreatic cancer cells
determined that QSOX1 plays a significant role in pan-
creatic tumor cell growth and metastatic potential. To
determine if QSOX1 overexpression may be functionally
relevant in other tumor types we performed immunohis-
tochemistry (IHC) on breast tissue microarrays and dis-
covered that the expression of QSOX1 is specific to
malignant breast tumors as well, and has diagnostic and
prognostic significance in publicly available microarray
datasets. These findings led us to hypothesize that over-
expression of QSOX1 might be functionally conserved
between pancreatic ductal adenocarcinoma and breast
adenocarcinoma, prompting further exploration of the
potential malignant function of QSOX1.
QSOX1 belongs to the family of FAD-dependent sulfhy-
dryl oxidases with expression in all sequenced eukaryotic
organisms to date, indicating that QSOX1 provides a sig-
nificant and highly conserved function among organisms.
The primary enzymatic function of QSOX1 is oxidation of
sulfhydryl groups, generating disulfide bonds in proteins,
ultimately reducing oxygen to hydrogen peroxide [6-8].
Previous work has reported the localization of QSOX1 to
the Golgi apparatus and endoplasmic reticulum in human
embryonic fibroblasts where it works independently as
well as with protein disulfide isomerase to help fold nas-
cent proteins in the cell [9-11].
In humans, QSOX1 is located on chromosome 1q24 and
alternative splicing generates a long (QSOX1-L) and short
(QSOX1-S) transcript [12]. Both, QSOX1-S and -L have
identical functional domain organization, although
QSOX1-L contains a predicted transmembrane domain
that is not present in QSOX1-S due to alternative splicing
in exon 12 [12]. While the majority of research to date has
focused on the sulfhydryl oxidase activity of QSOX1 to
efficiently generate disulfide bonds in proteins [8,13,14],
the major biological substrates of QSOX1 and the func-
tional significance associated with each QSOX1 splice var-
iant remain elusive.
Evidence supporting a pro-malignant role for QSOX1
expression has also been reported in prostate tumor
cells by Song and colleagues [15]. Using knockdown stu-
dies they were able to show that the loss of NKX3.1, a
transcription factor that is absent in 80% of metastatic
prostate cancers, dramatically increased expression of
QSOX1 in early stages of prostatic neoplasia and
throughout the progression of invasive prostate cancer,
but was not shown to be present in the normal prostate
[15]. NKX3.1 is a known tumor suppressor that is exclu-
sively expressed in luminal epithelial cells of the pros-
tate. This finding is consistent with our observation of
QSOX1 over-expression in the pancreas as well as in
breast adenocarcinoma [5].
In the present study, we evaluated QSOX1 protein
expression in breast adenocarcinoma cell lines MCF7,
BT474 and BT549 and in a breast tumor tissue microarray.
Using short hairpin RNA (shRNA) specific for QSOX1-S
and -L, we assessed the effects of QSOX1 knockdown on
cell growth, cell cycle, apoptosis, invasion and matrix
metalloproteinase activity. The loss of QSOX1 significantly
affected tumor cell proliferation and dramatically sup-
pressed tumor cell invasion through Matrigel™. The addi-
tion of exogenous recombinant human QSOX1 (rhQSOX1)
rescued the invasive capabilities of MCF7, BT474 and
BT549 validating the pro-invasive function of QSOX1. We
further report the mechanism of QSOX1-mediated invasion
in vitro is due, in part, to elevated MMP-9 activity.
Material and methods
Cell culture
Breast adenocarcinoma MCF7, MDA-MB-468, MDA-
MB-453, BT474, ZR75, BT549 and MDA-MB-231 cancer
cell lines were cultured in DMEM with 10% fetal bovine
serum (FBS) (Life Technologies, Grand Island, New
York, USA). Immortal human non-tumorigenic breast
epithelial cells (MCF10A) were cultured in Clontech
KGM-2 karotinocyte media (Gibco). All cell lines were
grown at 37°C with 5% CO2.
All cell lines tested negative for mycoplasma contami-
nation using the Venor GeM Mycoplasma Detection
Kit, (Sigma-Aldrich, St. Louis, Missouri, USA).
Immunohistochemistry (IHC) and scoring of staining
intensity
Breast tumor microarray slides were generated from 153
different breast cancer patients. Each patient’s tumor was
represented in triplicate on the slides. Immunohisto-
chemistry on breast tumor tissue microarray samples was
performed exactly as previously described [16]. After
staining the TMA slides with anti-QSOX1 rabbit polyclo-
nal antibody, a board certified pathologist (ITO) scored
the staining pattern as i) the percentage of cells with IHC
staining for QSOX1 protein expression in the core tumor
tissue sample (0: no staining, 1 (Low): 1 to 33%, 2 (Inter-
mediate): 34 to 66%, 3 (High): 67 to 100%), and ii) the
intensity of the antibody stain (0: no staining, 1: weak, 2:
moderate, 3: strong staining intensity).
All samples were pre-existing and de-identified and,
therefore, exempt from review by the human subjects
Institutional Review Board at Arizona State University.
Statistical assessment of QSOX1 IHC with molecular
subtypes of breast cancer
There were 153 patient tissue samples in triplicate
stained with anti-QSOX1 rabbit polyclonal Ab (Protein-
tech, Chicago, Illinois, USA). IHC staining was scored by
a board certified pathologist (ITO). The amount and
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intensity of QSOX1 staining/expression was scored on a
scale of 0 to 3. The first IHC score number represents
the percentage of cells staining (0: No staining, 1: 1 to
33%, 2: 34 to 66%, 3: 67 to 100%), and the second repre-
sents intensity (0: No staining, 1: weak, 2: moderate, 3:
strong staining intensity). We grouped the scores into
four categories: 0 (No staining), 11/12/21 (Low staining),
22/13/31 (Intermediate staining) and 32/33/23 (High
staining).
To evaluate the relationship between markers (Tumor
grade, Her2, CK5/6, and Ki-67) and QSOX1, Pearson’s
chi-square test was performed. Using two-sided
P-values, statistical significance will be set at P ≤ 0.05.
Generation of short hairpin (sh) RNA and lentiviruses
production
Two different shRNA for QSOX1 were obtained through
DNASU in the lentiviral pLKO.1-puromycin selection
vector. QSOX1 sh742, 5’ - CCGGGCCAATGTGGTGA-
GAAAGTTTCTCGAGAAACTTTCTCACCACATTG
GCTTTTTG - 3’ (sense), QSOX1 sh528, 5’- CCGGA-
CAATGAAGAAGCCTTT - 3’ (sense), and shScramble
with target sequence 5’ -TCCGTGGTGGACAGCCA-
CATG - 3’ was obtained from Dr. Josh LaBaer’s labora-
tory at Arizona State University. The target sequence is
underlined and each vector contains the same support-
ing sequence surrounding the target sequence. Lenti-
viruses containing sh742, sh528 and shScramble were
produced as previously reported by Katchman et al.
2011 [5].
Generation of shQSOX1-transduced tumor cell lines
Stable transduction of sh742, sh528 and shScramble into
MCF7, BT474 and BT549 cell lines was performed by first
seeding the cells at 6 × 105 cells/well in a six-well plate
and incubating overnight. The next day the cells were
transduced by adding 8 ug/mL polybrene (EMD Millipore
Corporation, Billerica, Massachusetts, USA) and 200 ul
sh742, sh528 and shScramble lentivirus produced from
293T cells to each well. The cells were then incubated for
24 hours. The following day, fresh DMEM with 10% FBS
was added, containing 1 ug/mL puromycin (Sigma) to
select for the transduced cells. QSOX1 knockdown was
measured by Western blot.
SDS-PAGE-Western blotting
Western blotting was performed using cell lysates from
MCF10A, MCF7, MDA-MB-468, MDA-MB-453, BT474,
ZR 75, BT549 and MDA-MB-231. Cell lysates were gener-
ated by harvesting 2.5 × 106 cells by centrifugation fol-
lowed by lysis using RIPA buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100)
with 1× SigmaFAST Protease Inhibitor Cocktail Tablet,
EDTA Free. Protein in the cell lysate was measured using
the micro BCA protein assay kit (Thermo Fisher Scientific,
West Palm Beach, Florida, USA). All samples were then
normalized to 2 mg/mL (20 ug total protein per lane).
Samples were run on 10% SDS-polyacrylamide gels then
transferred onto Immun-Blot™ PVDF Membranes (Bio-
Rad, Hercules, California, USA). Rabbit polyclonal anti-
QSOX1 (ProteinTech), rabbit polyclonal anti-alpha-tubulin
(Cell Signaling), rabbit polyclonal anti-MMP-2 and -9
(Sigma), mouse monoclonal caspase 3 (Cell Signaling
Technology, Danvers, Massachusetts, USA), and rabbit
polyclonal LC3 (Cell Signaling) antibodies were diluted
according to the manufacturer’s instructions and as deter-
mined in preliminary experiments, in 1% BSA in 1× TBS
+ 0.01% Tween-20 and incubated overnight. Goat anti-
rabbit or anti-mouse IgG-alkaline phospatase or HRP sec-
ondary antibody was used at a 1:5,000 dilution and incu-
bated with the blot for 1 h followed by washing. BCIP/
NBT substrate (Pierce Chemical, Rockford, IL, USA) was
added and the blot was developed at room temperature
(RT) for approximately 10 minutes for alkaline phospha-
tase secondary antibody. For samples incubated in goat
anti-rabbit or mouse HRP secondary antibody, the blots
were developed using Novex ECL Chemiluminescent Sub-
strate Reagent Kit (Novex Life Technologies, Grand
Islandm New York, USA). Quantification of band intensity
was measured using Image J (Abramoff, M.D., Magalhaes,
P.J., Ram, S.J. “Image Processing with ImageJ”. Biopho-
tonics International, volume 11, issue 7, pp. 36-42, 2004)
and is presented as percent change from the scrambled
shRNA control. Full gel images are available in the Addi-
tional file 1. All gel images were annotated and processed
using Adobe Photoshop CS3 (Adobe Systems Incorpo-
rated, San Jose, California, USA).
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay
Cells were seeded at 3 × 103 cells/well in a 96-well plate
in triplicate and incubated at 37°C, 5% CO2 over the
course of five days. The MTT assay was performed over
a five-day period according to the manufacturer’s instruc-
tions (Life Technologies Invitrogen-Molecular Probes,
Vybrant MTT Cell Proliferation Assay Kit, Grand Island,
New York, USA). Results are presented as mean +/- S.D.
Student’s two tailed t-test was performed to determine
significance.
Trypan Blue live/dead cell growth assay
Cells were seeded at 2.5 × 104 cells/well in a 12-well plate
in triplicate and incubated at 37°C, 5% CO2 over the
course of five days. The cells were removed with Cell
Stripper, pelleted and brought back up in 1 mL PBS.
A 30 ul aliquot was then used to determine total cell
number. The cells were stained at a 1:1 ratio with 0.1%
Trypan Blue and are reported as total number of live cells.
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RNA Isolation and cDNA Synthesis
Total RNA isolation was performed according to the
manufacturer’s instructions for animal cells using spin
technology (RNeasy Mini Kit, Qiagen, Gaithersburg,
Maryland, USA). After RNA was isolated from each
sample was reverse transcribed with qScript cDNA Syth-
esis Kit (Quanta Biosciences, Gaithersburg, Maryland,
USA) according to the manufacturer’s instructions.
Quantitative Real Time PCR (qPCR)
The relative level of GAPDH, QSOX1-L, QSOX1-S,
MMP-2 and MMP-9 were analyzed in each sample by
qPCR. Each cDNA sample was normalized to 100 ng/μl
in molecular grade water along with 100 nM final con-
centration of each primer and 1× final concentration of
PerfeCta SYBR Green Fast Mix (Quanta Biosciences,
Gaithersburg, Maryland, USA), ROX to a final volume
of 10 μl. qPCR was performed using PerfeCTa SYBR
Green FastMix, ROX from Quanta Biosciences (Quanta
Biosciences, Gaithersburg, Maryland, USA) on an
ABI7900HT thermocycler, Applied Biosystems Inc. (Life
Technologies, Grand Island, New York, USA) Reaction
protocol: initial denaturation was as follows - 95°C for
3 minutes; PCR Cycling (40 cycles) 1.) 95°C, 30 sec.
2.) 55°C, 30 sec. 3.) 72°C, 1 minute; Melt Curve (Disso-
ciation stage). The primer sequences for the genes ana-
lyzed are: GAPDH Forward 5’ - GGCCTCCAAGG
AGTAAGACC; GAPDH Reverse 5’ - AGGGGTCTACA
TGGCAACTG; QSOX1-S Forward 5’ - TGGTCTAGCC
ACAACAGGGTCAAT; QSOX1-S Reverse 5’ - TGTGG
CAGGCAGAACAAAGTTCAC; QSOX1-L Forward 5’ -
TTGCTCCTT GTCTGGCCTAGAAGT; QSOX1-L
Reverse 5’-TGTGTCAAAGGAGCTCTCTCTGTCCT;
MMP-2 Forward 5’ - TTGACGGTAAGGACGGA-
CTC; MMP-2 Reverse 5’ - ACTTGCAGTACTCCC-
CATCG; MMP-9 Forward 5’ - TTGACAGCGACAAG
AAGTGG; MMP-9 Reverse 5’ - CCCTCAGTGAAGCG
GTACAT. Each reaction was performed in triplicate with
the data representing the averages of one experiment.
In the shRNA experiment, expression of MMPs was
normalized to the non-targeted GAPDH to determine
ΔCq. ΔCq replicates were then exponentially transformed
to the ΔCq expression after which they were averaged ±
standard deviation. The average was then normalized to
the expression of the shScramble control to obtain the
ΔΔCq expression. Significance was determined using the
Student’s two tailed t-test.
Boyden chamber and invasion recovery assay
Invasion assays were performed using BD BioCoat™ BD
Matrigel™ and non-Matrigel™ control invasion chambers
(BD Biosciences, San Jose, California, USA) with 8.0 μm
pore size polyethylene terephthalate (PET) membrane
inserts in 24-well format. The assay was performed
according to the manufacturer’s instructions (BD
Bioscience, San Jose, California, USA). A total of 4 × 104
cells/well were seeded into the inner Matrigel™ chamber
in serum free DMEM. The outer chamber contained 10%
FBS in DMEM. MCF7, BT474 and BT549 cells were incu-
bated for 72, 48 and 48 hours, respectively at 37°C, 5%
CO2. For invasion rescue assays MCF7, BT474 and
BT549, cells were incubated with 50 nM rQSOX1 as well
as catalytically inactive mutant rQSOX1 (rQSOX1-AA).
Cells that invaded through the Matrigel™ and migrated
through the pores onto the bottom of the insert were fixed
in 100% methanol and then stained in hematoxylin (Invi-
trogen-Life Technologies, Grand Island, New York, USA).
The total number of invading cells was determined by
counting the cells on the underside of the insert from tri-
plicate wells (six fields per insert) at 20× magnification.
The extent of invasion was expressed as the mean +/- S.D.
Significance was determined using the Student’s two-tailed
t-test. Results presented are from one of three indepen-
dent experiments.
Gelatin zymography
The identification of MMP was performed using gelatin
zymography. Zymography experiments were performed
essentially as previously described by Katchman et al. [5].
Minor changes in the protocol are the inclusion of
untreated MCF7 and BT549 cells as well as short hairpin-
transduced cells were seeded at 5 × 105 cells/well (12-well
plates) in DMEM with 10% FBS. The next day, cells were
then washed with 1 × PBS and the media was changed to
serum-free DMEM and incubated for 48 hours instead of
24 hours before being collected and protein concentra-
tions determined using a BCA assay. Quantification of
band intensity was measured using Image J and is pre-
sented as the percent change from the scrambled shRNA
control.
Results
Expression of QSOX1 correlates with poor prognosis in
patients with Luminal B breast cancer
Bioinformatic analysis of QSOX1 transcript expression
was assessed using data from the Gene expression based
Outcome for Breast cancer Online algorithm (GOBO)
[17]. GOBO is a web based analysis tool that utilizes
Affymetrics gene expression data curated from 1,881
breast cancer patients with associated stage, grade, nodal
status and intrinsic molecular classification based on the
paradigm first reported by the Perou Laboratory [18].
Expression of QSOX1 was significantly higher in ER+
tumors compared to ER- (P-value < 0.00001), with the
highest expression observed in Luminal A, Luminal B
and Normal-like subtypes (Figure 1a, b). The lowest
QSOX1 transcript expression was observed in HER2-
enriched and basal tumors. Using the GOBO tool, we
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performed a series of Kaplan Meier analyses to determine
whether QSOX1 expression is associated with relapse free
survival (RFS) and overall survival (OS) (Figure 1c, d and
Additional file 2). While elevated QSOX1 expression is
not associated with survival when considering all breast
tumor subtypes together (see Additional file 2), it is
highly associated with poor RFS (P = 0.00062) and OS
(P = 0.00031) in Luminal B tumors (Figure 1c, d). The
expression of QSOX1 correlates with increasing tumor
grade as well as poor overall survival in patients diag-
nosed with grade 2 (P = 0.04242) and grade 3 (P =
0.07095) breast tumors (see Additional file 2i-k). Elevated
QSOX1 was also associated with reduced OS in luminal
A tumors (see Additional file 2g, h) and is a predictor of
poor OS for patients who did not receive systemic treat-
ment (see Additional file 2d).
Evaluation of QSOX1 expression by
immunohistochemistry
Results from the GOBO transcript expression analysis
fueled investigation of QSOX1 at the protein level in breast
tumors. A breast tumor tissue microarray composed of
breast tumors from over 150 different patients was stained
with a rabbit anti-QSOX1 polyclonal antibody and scored
by a board certified pathologist (ITO). Figure 2b shows no
expression of QSOX1 in normal breast tissue. Figure 2c-f
Figure 1 GOBO analyses of QSOX1 transcript expression among subtypes of breast cancer from over 1,800 cases. a) Box plot analysis of
QSOX1 mRNA expression in all tumors ER+ (n = 1,225) and ER- tumors (n = 395) (P < 0.00001); b) Box plot analyses of QSOX1 expression among
HU subtypes, Basal (n = 357), HER2 (n = 152), Luminal A (n = 482), Luminal B (n = 289), Normal-like (n = 257) and unclassified (n = 344), (P <
0.00001). c) Kaplan Meier analysis over 10 years of relapse free survival (RFS) in patients with Luminal B breast cancer expressing high (red line)
and low (gray line) QSOX1 mRNA; High (n = 56), low (n = 74), (P = 0.00062) and d) Overall survival (OS); High (n = 34), low (n = 64), (P =
0.00031). Data obtained using GOBO, Gene expression based Outcome for Breast cancer Online.
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represent a pattern of increasing QSOX1 expression
observed in the TMA in grade 1, grade 2 and grade 3 inva-
sive ductal carcinomas and a grade 3 invasive lobular car-
cinoma. Statistical evaluation of QSOX1 expression by
immunohistochemistry (IHC) demonstrated an association
with ER+ tumors, and a strong association with high Ki-67
expression in patients with a high QSOX1 IHC score
(Figure 2a, Table 1). There was no relationship observed
for QSOX1 expression in HER2+ tumors or cytokeratin
markers (CK 5/6) positive tumors. These data are consis-
tent with the correlation observed in the GOBO data.
Interestingly, higher grade tumors were associated with a
higher QSOX1 IHC score (Figure 2a, Table 1). Conversely,
lower QSOX1 protein expression is significantly associated
with lower grade tumors. This is consistent with an asso-
ciation between QSOX1 expression and more aggressive
ER+ tumors.
Evaluation of QSOX1 expression by Western blot
QSOX1 expression in human breast adenocarcinoma was
assessed in six different breast tumor cell lines, and a
transformed non-tumorigenic breast cell line, MCF10A
[19,20]. Similar to our previous studies in pancreas cancer
[5], the short form of QSOX1 is expressed as the predomi-
nant splice variant in each cell line examined (Figure 3a).
Consistent with the GOBO and IHC expression data, we
found that the expression of QSOX1-S protein was more
highly expressed in luminal-like cell lines MCF7 (ER+),
MDA-MB-453 (ER-), ZR 75 (ER+) and BT474 (ER+) com-
pared to basal-like BT549 and MDA-MB-231 cell lines.
Interestingly, QSOX1 was most weakly expressed in trans-
formed normal MCF10A cells which do not form tumors
in immunodeficient animals.
Expression of QSOX 1 in tumor cells promotes cellular
proliferation
To begin to assess the mechanistic role that QSOX1 plays
in tumor cells we stably knocked-down QSOX1 expression
in MCF7, BT549 and BT474 cells using two lentiviral
shRNA constructs, sh742 and sh528 (Figure 3b-d). QSOX1
protein expression was assessed following stable knock-
down relative to isogenic parental cell lines by Western
Figure 2 Protein expression of QSOX1 is specific for breast tumor cells in tissue. a.) Graphical representation of “High QSOX1 staining (n = 65)”
column from Table 1. Each graph correlates with percentages of QSOX1 positive cells listed in Table 1 for the “High QSOX1 staining (n = 65)” column
b.) normal breast tissue showing no QSOX1 staining; c.) grade 1 invasive ductal carcinoma (IDC) ER+ PR+ breast tumor tissue showing low QSOX1
staining; d.) grade 2 IDC ER+ PR+ breast tumor tissue showing moderate QSOX1 staining; e.) grade 3 IDC, ER+, PR+ showing high QSOX1 staining; f.)
grade 3 invasive lobular carcinoma (ILC), ER+, PR- showing high QSOX1 staining. Polyclonal antibody recognizes residues 1-329 of both QSOX1-S and -L.
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blotting. Densitometry of the QSOX1 protein relative to
alpha-tubulin expression indicates that sh742 and sh528
resulted in a knock-down of QSOX1-S expression in
MCF7 cells by 85% and 82%, respectively. In BT549 cells
the knock-down was 65% and 77%, and for BT474 cells by
40% and 36%, respectively (Figure 3b-d).
The growth rates of shQSOX1-transduced MCF7,
BT549 and BT474 cells were then evaluated compared to
isogenic controls (Figure 3e-j). An equal number of
untransduced (parental), shScramble, sh742 and sh528
cells were seeded in 96-well plates and assayed for prolif-
eration over five days using the MTT assay. ShQSOX1-
transduced MCF7, BT549 and BT474 cells displayed a
decrease in cell growth compared to shScrambled and par-
ental controls (Figure 3e-g). In MCF7 cells, sh742 and
sh528 showed a 66% decrease in cell growth, while sh742
and sh528 suppressed growth of BT549 by 78% and 69%,
respectively, and sh742 and sh528 suppressed growth of
BT474 by 52% and 29%, respectively by Day 5. We con-
firmed our MTT results by performing Trypan Blue stain-
ing over five days (Figure 3h-j) using the same incubation
conditions as in the MTT assay. These results suggest that
QSOX1 helps drive tumor cell growth.
Cell cycle, apoptosis and autophagy analysis
In non-tumor fibroblasts, expression of QSOX1 was cor-
related with the quiescent stage, Go, of the cell cycle
and overexpression of QSOX1 was shown to protect
MCF7 cells for ROS mediated apoptosis [21], this led us
to hypothesize that a shQSOX1-mediated decrease in
cell proliferation could be the result of abnormal regula-
tion of the cell cycle, an increase in apoptosis or the
result of autophagosome formation. To address this,
propidium iodide (PI) was used in flow cytometry to
evaluate the effects of shQSOX1 on cell cycle. In MCF7
cells, both shQSOX1 RNAs showed a slight decrease in
G1 and an increase (11 to 12%) in S phase, while in
BT474 cells both shQSOX1 RNAs showed a slight 12%
increase in G1 and a 26% decrease in S phase but
neither shQSOX1 RNA sequence had any effect in
BT549 cells compared to untreated and shScramble
controls (see Additional file 3a-c).
Table 1 Statistical assessment of QSOX1 protein expression with molecular subtypes of breast cancer
IHC Score P-value
No QSOX1 staining
(n = 17)
%
Low QSOX1 staining
(n = 47)
%
Intermediate QSOX1 staining
(n = 24)
%
High QSOX1 staining
(n = 65)
%
Grade *0.0003
1 53.3 42.2 25 10.8
2 33.3 33.3 41.7 32.3
3 13.3 24.4 33.3 56.9
ER *0.0013
ER + 80 89.1 73.9 55.4
ER - 20 10.9 26.1 44.6
HER2 0.0811
HER2 + 11.8 6.4 29.2 14.1
HER2 - 88.2 93.6 70.8 85.9
CK5/6 0.0733
CK5/6 - 100 95.7 87.5 83.1
CK5/6 + 0 4.3 12.5 17
KI-67 *0.0011
Low 33.3 33.3 41.1 18.5
Intermediate 44.4 45.5 17.7 16.7
High 22.3 21.2 41.2 64.8
ER & HER2 *0.0016
ER- HER2 - 13.3 8.7 8.7 35.9
Others 86.7 91.3 91.3 64.1
ER, HER2 and CK5/6 0.0923
ER- HER2-, CK5/6: 1/2/3 0 4.3 4.2 15.4
Others 100 95.7 95.8 84.6
QSOX1 expression was grouped into four categories based on the percentage of cells stained and the intensity of QSOX1 expression: No expression, Low QSOX1
expression, Moderate QSOX1 expression and Strong QSOX1 expression (see material and methods for detailed explanation). Each number represents the
percentage of QSOX1 positive or negative cells within each molecular subtype of breast cancer (n = total number of tissue samples within each category).
Pearson’s chi-square test was performed to determine a relationship between the molecular subtypes and QSOX1 expression. Statistical significance using a two-
sided P-value was set at P ≤0.05*.
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Next we determined if the decrease in cellular prolifera-
tion was due to an increase in apoptosis or autophagy (see
Additional file 3d, e). To assess apoptosis, we analyzed
MCF7 and BT474 transduced cells for Annexin V/PI [22].
We subsequently probed MCF7 and BT549 transduced
cells for LC3, a protein that is necessary for autophago-
some formation [23]. If the expression of QSOX1 pre-
vented cellular apoptosis or autophagy we would expect to
see an increase in expression of Annexin V and LC3 in
shQSOX1 transduced cells, but we did not observe any
statistically significant increases in Annexin V positive
cells (see Additional file 3d-f). This correlates with our
previous results in pancreas cancer that the suppression of
QSOX1 does not lead to cell death or autophagy.
Suppression of QSOX1 expression inhibits tumor cell
invasion
The process of tumor cell invasion involves the degrada-
tion of basement membrane (BM) components such as
laminin, collagen and fibronectin before a tumor cell is
Figure 3 Reduced expression of QSOX1 leads to a significant decrease in tumor cell growth. a) Western blot showing weak expression of
QSOX1 in transformed, but non-tumor-forming MCF10A and human breast ductal carcinoma cell lines Luminal A like (MCF7 and MDA-MB-453),
Luminal B like (ZR75 and BT474) and Basal like (BT549 and MDA-MB-231). a-Tubulin loading control is shown below each lane. MCF7, BT549 and
BT474 breast tumor cell lines were transduced with lentiviral shRNA QSOX1 (sh742 and sh528). Western blots are shown using the same anti-
QSOX1 polyclonal Ab as in Figure 2 on cell lysates from b.) MCF7 (percent decrease in sh742: 85% and sh528: 82%); c.) BT549 (percent decrease
in sh742: 45% and sh528: 77%) and d.) BT474 (percent decrease in sh742: 40% and sh528 36%) cells. Western blots have been cropped and full
images can be viewed in Additional file 1. (e-g) MTT and (h-j) Trypan Blue growth assays on MCF7, BT549 and BT474 cells transduced with
shScramble, sh742 and sh528 assayed on Days 1 through 5. Percent decrease sh742 and sh528 day 5: e.) 66% (both); f.) 78% and 69%; g.) 52%
and 34%; h.) 72% and 73%; i.) 98% and 96%; j.) 50% (both). Experiments were performed three times in triplicate; error bars represent SD from
triplicate wells. Significance **, P < 0.01.
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able to invade other tissues [24]. We performed a modi-
fied Boyden chamber assay using Matrigel™-coated
inserts in which tumor cells must degrade the Matrigel™
and migrate through a membrane with 8 um pores to
gain access to nutrient rich media. Sh742 and sh528-
transduced MCF-7, BT549 and BT474 tumor cells were
added to Matrigel-coated, 8 um pore inserts in serum-
free medium. After 72 (MCF7) and 48 (BT549 and
BT474) hours of incubation, tumor cells that were able to
degrade Matrigel™ and migrate through 8 um pores
onto the underside of the insert were counted (Figure 4a-
c). Our results demonstrate that knockdown of QSOX1
expression in MCF7 leads to a 65% and 71% reduction in
invasion of sh742 and sh528 transduced tumor cells,
respectively. For BT549 sh742 and sh528 - transduced
tumor cells, 60% and 40% decreases in invasion through
Matrigel™ were observed. Suppression of QSOX1
expression in BT474 cells leads to an 85% reduction in
invasion of both sh742 and sh528 transduced tumor
cells. These data suggest that QSOX1 plays a role in regu-
lating invasive behavior in vitro irrespective of breast
tumor subtype and hormone receptor status.
To prove that suppression of QSOX1 protein expression
was responsible for loss of tumor cell invasion, we per-
formed a rescue experiment in which recombinant human
QSOX1 (rhQSOX1, generously provided by Dr. Colin
Thorpe) was added to shQSOX1-MCF7, shQSOX1-BT549
and shQSOX1-BT474 cells during the invasion assay. As a
control for the enzymatically active QSOX1, a mutant
rhQSOX1 in which the CxxC motif in the thiredoxin-1
domain was mutated to AxxA (rhQSOX1(AA), generously
provided by Dr. Debbie Fass) was added to the invasion
assay. Addition of enzymatically active rhQSOX1 rescued
the invasive phenotype of the shQSOX1-transduced tumor
cells (Figure 4d-f), while the addition of the rhQSOX1(AA)
did not rescue invasion of the shQSOX1-transduced
tumor cells.
Decrease in QSOX1 leads to a decrease in matrix
metalloproteinase activity
Since knockdown of QSOX1 resulted in decreased breast
tumor cell invasion, it was important to determine a
mechanism for how QSOX1 might facilitate invasion.
Matrix metalloproteinases (MMP) have been shown to
play key roles in breast tumor invasion and metastasis
[24]. Both MMP-2 and -9 mRNA and protein levels have
been shown to contribute to breast tumor invasion, metas-
tasis and angiogenesis [25]. Since previous work demon-
strated that QSOX1-S is secreted into the extracellular
matrix where MMPs are activated, we hypothesized that
QSOX1 might help activate MMP-2 and -9 proteins.
MCF7 and BT549 cells transduced with shScramble,
sh742 and sh528 were plated at equal densities and
allowed to incubate in serum free media for 48 hours,
after which the supernatants were collected and analyzed
by gelatin zymography to determine if the loss of QSOX1
leads to a decrease in the functional activity of MMP-2
and -9.
Initial analysis of the results indicates that MCF7 and
BT549 possess similar MMP profiles even though it is
known that BT549 cells are more invasive. Luminal B-like
breast tumor cell lines BT474 and ZR75 do not secrete
detectable levels of MMPs [25,26]. However, both MCF7
and BT549 supernatants contain MMP-9 homodimer (130
kDa), a large amount of proteolytically active pro-MMP-9
(92 kDa) with lesser concentrations of proteolytically
active pro-MMP-2 (72 kDa).
We found that supernatants from MCF7 cells trans-
duced with sh742 and sh528 showed a 70% and 77%
decrease, respectively, in pro-MMP9 activity compared to
shScramble (Figure 5a). MCF7 supernatants from cells
transduced with sh742 and sh528 also showed a 50% and
60% decrease in active MMP-9 (a-MMP-9) as well
(Figure 5a). Supernatants from BT549 cells transduced
with sh742 and sh528 showed a 34% and 88% decrease,
respectively, in MMP-9 (Figure 5b). Decreases in the pro-
teolytic activity of MMP-9, using gelatin as a substrate,
provide a mechanism for the shQSOX1-mediated sup-
pression of invasion through Matrigel™.
To extend our hypothesis that QSOX1 is activating or
modifying MMPs post-translationally, we performed a
Western blot on total cell lysate from MCF7 and BT549
transduced cells as well as performed quantitative real
time PCR (qPCR) to determine if the loss of QSOX1
affected MMP protein and RNA levels (Figure 5c, d). Our
results indicate that the intracellular amount of MMP-2
and -9 protein is similar between the untreated, shScram-
ble, sh742 and sh528 samples in MCF7 and BT549 cells
(Figure 5c). Figure 5d demonstrates that the loss of
QSOX1 also has no significant effect on the transcrip-
tional activity of MMP-2 and -9. These results add confi-
dence to our hypothesis that QSOX1 is involved in the
post-translational activation of MMPs.
Discussion
QSOX1 protein was reported by our laboratory to be
over-expressed in tumors from patients diagnosed with
pancreatic ductal adenocarcinoma (PDA) [4]. In a subse-
quent study we reported that expression of QSOX1 pro-
motes pancreatic tumor cell growth and invasion [5]. To
determine if QSOX1 was also over-expressed in breast
cancer, a GOBO analysis was performed using data
from over 1,800 breast cancer cases. A prominent find-
ing in this analysis is that the highest levels of QSOX1
expression in Luminal B breast cancer correlate with very
poor RFS and OS (Figure 1c, d; Additional file 2e, f). The
median survival in patients with Luminal B breast cancer
who over-express QSOX1 is approximately four years.
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Figure 4 QSOX1 promotes tumor cell invasion. a.) MCF7, b.) BT549 and c.) BT474 cells transduced with shSramble, sh742 and sh528 shRNAs
were seeded at equal densities in the top chamber of Matrigel™ invasion wells and allowed to incubate for 48 (BT549 and BT474) and 72
(MCF7) hours, after which cells that had digested MatrigelTM and migrated through the 8 um pores were counted on the underside of the insert.
Representative 20× images are presented. MCF7 cells transduced with sh742 and sh528 show a 65% and 71% decrease in invasion. BT549 cells
transduced with sh742 and sh528 showed a 60% and 40% decrease in invasion. BT474 cells transduced with sh742 and sh528 show an 82%
decrease in invasion. Each knockdown was compared to shScramble controls. The invasive phenotype of shQSOX-transduced MCF7 (d.), BT549
(e.) and BT474 (f.) cells was rescued by exogenous incubation with catalytically active rhQSOX1. rhQSOX1 (AA) mutant is a mutant without
enzymatic activity, generously provided by Dr. Debbie Fass. Graphs represent average ± SD (MCF7, BT549 and BT474 n = 3), significance *, P <
0.05, ** P < 0.005.
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The prognostic power of QSOX1 expression for RFS and
OS increases when Luminal B breast cancer cases are
divided into quintiles using the GOBO analysis tool for
which patients with the highest fifth expression of
QSOX1 have RFS of less than two years and OS of less
than three years (see Additional file 2e, f). In support of
our GOBO analysis, showing that expression of QSOX1
is an indicator of poor OS and RFS in Luminal B breast
cancer patients, we performed IHC on breast TMA sam-
ples. We were able to confirm that expression of QSOX1
significantly correlates with ER+ breast tumor (P =
0.0013) cells as well as correlating with high Ki-67
expression (P = 0.0011), further supporting a role for
QSOX1 in cellular proliferation (Figure 2a). Additionally,
over-expression of QSOX1 mRNA in the GOBO analysis
and high levels of protein in IHC correlate with increas-
ing tumor grade in our breast tumor TMA analyses
(Figure 2; Table 1; Additional file 2i-k). Expression of
QSOX1 did not correlate with survival in HER2 enriched
tumors, ER- tumors or in tumors subtyped as basal-like.
Importantly, in patients who did not receive systemic
therapy (presumably due to diagnosis of very early stage
disease), QSOX1 appears to be a predictor of poor OS
(see Additional file 2d). However, this association was
not strong until more than five years post diagnosis.
These data collectively suggest that QSOX1 is associated
with highly proliferative ER+ tumors and warrants
further preclinical and prospective validation as a diag-
nostic and prognostic biomarker in ER+ tumors.
Tumor cells in which QSOX1 expression was sup-
pressed using shRNAs grew at less than half the rate of
shScramble and untreated controls in MCF7, BT549 and
BT474 cells (Figure 3e-j). The results of the MTT and
Trypan Blue assays confirm our breast TMA findings
Figure 5 Reduced expression of QSOX1 in MCF7 and BT549 cells leads to a decrease in functional MMP-9 activity. Gelatin zymography
of a) MCF7 and b) BT549 conditioned media shows a decrease in MMP-9 homodimers (130 kDa) and MMP-9 (92 kDa). The percent decrease in
MMP-9 expression in MCF7 was: sh742: 70% (P = 0.0171); sh528: 77% (P = 0.0182), and in BT549 was: sh742: 34% (P = 0.0531); sh528: 88% (P =
0.0564) compared to shScramble control. c) Western blots of total cell lysate from shRNA treated MCF7 and BT549 probing for MMP-2 and -9
show insignificant changes compared to shScramble control. Full images can be seen in Additional file 1. d) QPCR of QSOX1 transcripts and
MMP-2 and -9 transcripts. The graph represents relative gene expression calculated as ΔΔCq using GAPDH as the endogenous reference gene.
MMP-2 - MCF7 sh742 (P = 0.5294), sh528 (P = 0.2112); BT549 sh742 (P = 0.0054), sh528 (P = 0.0019). MMP-9 - MCF7 sh742 (P = 0.3981), sh528
(P = 0.3385); BT549 sh742 (P = 0.4192), sh528 (P = 0.0701). Average ± SD; significance was determined using a Student’s two-tailed t-test.
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showing that high expression of QSOX1 correlates with
high Ki-67 expression. Our attempt to explain the
decrease in cell growth by abnormal cell cycle regulation,
apoptosis and autophagy suggests that QSOX1 is not
involved in apoptosis, or autophagy (see Additional file
3d-f), but may marginally affect cell cycle, as we observed
a stall in G1 and an increase in S phase in MCF7 cells
(luminal-like) and an insignificant increase in G1 and a
decrease in S phase in BT474 (luminal-like) cells com-
pared to shScramble controls (Additional file 3a-c). How-
ever, there were no observable changes in BT549 cells
(basal-like). These results, combined with our findings in
PDA suggest that QSOX1 is unlikely to play a significant
role in cell cycle. Our analysis of apoptosis and autophagy
as a second possible mechanism contributing to the
observed decrease in cell growth did not reveal signifi-
cant increases in Annexin V/PI or LC3 expression
(autophagy) in our shRNA treated cells (see Additional
file 3d-f). We also did not observe any increases in Try-
pan Blue positive cells during our cell growth assays
compared to our shScramble control (data not shown).
At this time, the exact function of QSOX1 with respect to
tumor cell proliferation remains elusive.
The ability of a tumor cell to invade is one of several
hallmarks of cancer [27]. Based on our previous results
showing that QSOX1 over-expression in pancreas tumor
cells contributes to invasion, we hypothesized that the
over-expression of QSOX1 in breast adenocarcinoma
would elicit a similar phenotype. MCF7, BT549 and
BT474 cells transduced with QSOX1 shRNAs exhibited
significant decreases in their ability to degrade basement
membrane components and invade through Matrigel™
(Figure 4a-c). MCF7 cells are a poorly invasive, luminal-
A like breast cancer cell line, while BT549 (basal-like)
and BT474 (Luminal-B like) cells are highly invasive
[28,29]. Although the invasive capabilities are dramati-
cally different between these cell lines, QSOX1 knock-
down suppressed growth and invasion in all cell lines
irrespective of the level of QSOX1 expression (Figure 2a)
and molecular tumor subtype. Addition of exogenous
recombinant QSOX1 protein to shQSOX1 transduced
tumor cells rescued their invasive properties (Figure 4d-f),
confirming previous data suggesting that QSOX1 is
secreted into the extracellular matrix.
These findings indicate the advantage that QSOX1 pro-
vides to breast and pancreas tumors may be highly con-
served and universal among other tumor types. However,
one cannot draw this definitive conclusion from the phe-
notypic behavior of cells cultured in 2D [30,31]. What we
can conclude from our human TMA analysis of QSOX1
protein expression is that QSOX1 is a very specific marker
of tumor cells and that the expression of QSOX1 corre-
lates with increased proliferation (high Ki-67) and an
increase in tumor grade consistent with the characteristics
of highly invasive tumors. QSOX1 is likely to become func-
tionally relevant when considered not only in specific
molecular subcontext (such as ER+ tumor cells), but in
specific environmental contexts within the 3D breast
tumor microenvironment with the full complement and
complex interplay of autocrine and paracrine signaling
components known to be important in tumor progression
[28,30,32,33].
MMPs are a family of proteases that are involved in the
degradation of basement membrane components contri-
buting to tumor cell invasion and proliferation [34]. In
breast tumors, gelatinases, MMP-2 and MMP-9 have
been shown to play a significant role in growth and
metastasis, as their expression is correlated with aggres-
sive forms of breast cancer [25,34,35]. Gelatinases are
secreted into the extracellular matrix in their inactive,
pro- form where they can be activated through either a
cysteine switch or shift in the prodomain mediated by
integrins and laminin in basement membranes and struc-
tural proteins, such as vimentin [25]. Thiol binding pro-
teins, such as glutathione, have also been shown to help
fold and activate MMPs [35]. Our data suggest that
MMPs could be one substrate of QSOX1. To address this
we performed gelatin zymography to assess functional
activity MMPs. Our data reveal that knockdown of
QSOX1 protein expression in both MCF7 and BT549
cells leads to a decrease in MMP-9 functional activity
compared to shScramble control (Figure 5a, b). While
the functional activity of MMP-2 and -9 was suppressed,
mRNA encoding MMP-2 and -9 remained relatively
constant in MCF-7 cells and increased in BT549 cells
(Figure 5c, d). BT474 cells unfortunately do not express
or secrete levels of MMP-2 and -9 detectable by gelatin
zymography [25,36]. Interestingly, when we knock down
QSOX1 in BT474 cells we observe the same phenotypic
effects indicating that there are multiple substrates of
QSOX1 contributing to our observed decrease in cellular
proliferation and invasion. Taken together, the data sug-
gest that QSOX1 may post-translationally activate MMPs,
although this requires further study to be a definitive
conclusion. Future proteomic analysis may reveal a wide
spectrum of substrates linked to cellular proliferation,
basement membrane production and cellular motility
connecting the phenotypes observed in this report to
QSOX1 expression.
QSOX1 is expressed during embryonic development in
mouse and rat during key migratory stages [37]. This
developmental data combined with our results indicating
that QSOX1 expression facilitates degradation of base-
ment membranes suggests that tumor cells over-express
QSOX1 to allow them to break down basement mem-
branes and invade into adjacent tissues or into circula-
tion. It will be interesting to assess QSOX1 expression in
circulating tumor cells. QSOX1 expression in Luminal B
Katchman et al. Breast Cancer Research 2013, 15:R28
http://breast-cancer-research.com/content/15/2/R28
Page 12 of 14
subtype may help further stratify which tumors are likely
to be more aggressive, leading to poor overall survival.
Notably from these data we can project that targeting
QSOX1 irrespective of tumor subtype could help to slow
tumor cell proliferation as well as tumor cell invasion.
This finding provides another tool for physicians and
their patients to decide whether to more aggressively
treat patients with Luminal B breast cancer whose
tumors express high levels of QSOX1.
While this paper was under review and revision, Perno-
det et al. reported that QSOX1 over-expression in breast
cancer is associated with a good prognosis. This report
creates a discrepancy of the function of QSOX1 in breast
cancer. We previously published that QSOX1 promotes
pancreatic cancer growth and invasion in a manner very
similar to the results shown here. We became interested
in the role of QSOX1 in breast cancer after we employed
the publicly available GOBO analysis tool to evaluate
QSOX1 gene expression among 1,881 cases of molecularly
subtyped breast cancer. The GOBO analysis clearly indi-
cates that QSOX1 expression predicts a poor prognosis in
patients with luminal type and normal-like breast cancer.
This initial GOBO analysis fueled our investigation of
QSOX1 in breast cancer. Unlike the 217 patient dataset
used by Pernodet et al., GOBO analysis is completely
independent, and agrees with our findings that QSOX1 is
a bad actor in breast cancer. Furthermore, we have shown
immunohistochemically that higher grade tumors express
more QSOX1 protein than lower grade tumors. It will be
interesting to determine the true role of QSOX1 in breast
and other cancers.
Conclusions
In this study we show for the first time that QSOX1
over-expression is associated with features of poor prog-
nosis in patients whose tumors highly express QSOX1
and that QSOX1 promotes breast tumor growth and
invasion in vitro, perhaps mediated mechanistically by
post-translational activation of MMP-9 functional activ-
ity. While further research is still needed to understand
the role of QSOX1 in vivo, the results presented here
strongly suggest that targeted inhibition of QSOX1 may
stall cancer progression.
Additional material
Additional file 1: Full Western blot and gelatin zymography images.
a) Western blot of MCF10A confluent, MCF10A 30% confluent, MCF7,
MDA-MB-468, MDA-MB-543, BT549 and MDA-MB-231 total cell lysate
probing for QSOX1 and Bactin. b) Western blot of MCF7 Untreated,
shScramble, sh742, sh528, sh616 and sh613 total cell lysate probing for
QSOX1. c) Western blot of BT549 untreated, shScramble, sh742, sh528
and sh616 total cell lysate probing for QSOX1. d) Western blot of MCF7
untreated, shScramble, sh742, sh528, sh616 and sh613 probing for alpha-
tubulin. e) Western blot from left to right MCF7 untreated, shScramble,
sh742, sh528 and sh616; BT549 untreated, shScramble, sh742, sh528 and
sh616; H2O2 treated MCF7 cells, probing for alpha-tubulin. f) Western
blot of MCF7 Untreated, shScramble, sh742, sh616 and sh528 probing for
Vimentin. g) Western blot from left to right MCF7 untreated, shScramble,
sh742, sh528 and sh616; BT549 untreated, shScramble, sh742, sh528 and
sh616; H2O2 treated MCF7 cells, probing for LC3. h) Western blot of
BT549 untreated, shScramble, sh742, sh528 and sh616 probing for
Vimentin. i) Western blot of BT549 untreated, shScramble, sh742, sh528,
sh616 and sh613 probing for alpha-tubulin. j) Western blot from left to
right MCF7 untreated, shScramble, sh742, sh528 and sh616; BT549
untreated, shScramble, sh742, sh528 and sh616; H2O2 treated MCF7 cells,
probing for caspase 3. k) Gelatin zymography of BT549 untreated,
shScramble, sh742, sh528 and sh616. Clear bands indicated MMP-2 and
-9 digestion. l) Gelatin zymography of MCF7 untreated, shScramble,
sh742 ad sh528. Clear bands indicate MMP-2 and -9 digestion. m)
Western blot of, from left to right, MCF7 untreated, shScramble, sh742
and sh528; BT549 untreated, shScramble, sh742 and sh528. Blot was
probed for MMP-2, then stripped and reprobed for MMP-9. n) Western
blot of ZR75, BT474 and MCF7 Untreated, shScramble, sh742 and sh528
probing for QSOX1. o) Western blot of BT474 untreated, shScramble,
sh742 and sh528 probing for QSOX1 and alpha-tubulin.
Additional file 2: GOBO (Gene expression based outcome for breast
cancer online) analyses of QSOX1 gene expression. For a-d and g-k,
gray line represents tumors weakly expressing QSOX1 transcript; red line
represents tumors strongly expressing QSOX1 transcript. Kaplan-Meier
analysis using relapse free survival (RFS) and overall survival (OS) as an
endpoint for a.) All Tumors - RFS (n = 914); b.) All Tumors - OS (n = 737);
c.) Untreated Tumors - RFS (n = 415); d.) Untreated Tumors - OS (n =
307); e.) Luminal B - RFS (n = 130); f.) Luminal B - OS (n = 98); stratified
into five quintiles based on QSOX1 expression level. Purple line
represents the highest fifth of QSOX1 expression where 50% median RFS
is less than two years for RFS and less than three years for OS. g.)
Luminal A - RFS (n = 261); h.) Luminal A - OS (n = 189); i.) Grade 1 - OS
(n = 139); j.) Grade 2 - OS (n = 315); k.) Grade 3 - OS (n = 262).
Additional file 3: Suppression of QSOX1 in MCF7 and BT549 cells
does not lead to a significant increase in apoptosis or autophagy.
a.) MCF7, b.) BT549 and c.) BT474 cells treated with shRNAs were
analyzed for deviations in the cell cycle. Analysis was performed using
propidium iodide to label DNA and analyze cells in G1, S and G2/M of
the cell cycle by flow cytometry. Annexin V/Propidium Iodide analysis
was performed on d.) MCF7 and e.) BT474 cells to assess apoptosis.
Western blot analysis of a) MCF7 and BT549 untreated, shScramble,
sh742 and sh528 total cellular protein probed for LC3. BT549 cells
incubated exogenously with 50 uM H2O2 to induce expression of LC3
(autophagy) is used as a positive control. Full gel images can be seen in
Additional file 1.
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